Press-release for stocks related to iot for pdsb

Prices are updated after-hours

tags : Iot symbols : Pdsb

save search

PDS Biotech Announces Achievement of an Enrollment Objective in National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based Combination in Advanced HPV-Associated Cancers
Published: 2022-03-15 (Crawled : 12:00) - globenewswire.com
PDSB | $3.165 5.85% 180K

Health Technology

| -41.14% | O: 0.2% H: 7.86% C: 7.27%
pds0101 phase 2 hpv trial cancer biotech iot tiona enroll

PDS Biotechnology to Present at the 32nd Oppenheimer Annual Healthcare Conference
Published: 2022-03-01 (Crawled : 15:00) - biospace.com/
PDSB | $3.165 5.85% 180K

Health Technology

| -50.0% | O: -0.5% H: 3.61% C: -0.67%
health thc technology conference biotech iot

PDS Biotech Announces Preliminary Safety Data on PDS0101 in Combination With KEYTRUDA® (pembrolizumab) at the 2022 Multidisciplinary Head and Neck Cancers Symposium
Published: 2022-02-24 (Crawled : 15:30) - globenewswire.com
PDSB | $3.165 5.85% 180K

Health Technology

| -47.45% | O: -7.03% H: 14.74% C: 13.42%
pds0101 keytruda symposium cancer head and neck biotech iot

PDS Biotech Announces Clinical Trial with Mayo Clinic to Study PDS0101 in Early Stage Pre-Metastatic- HPV-Associated Head and Neck Cancer
Published: 2022-02-15 (Crawled : 14:30) - biospace.com/
PDSB | $3.165 5.85% 180K

Health Technology

| -56.22% | O: 2.78% H: 4.42% C: -1.71%
pds0101 ces hpv trial cancer head and neck biotech iot

PDS Biotech Announces Preliminary Efficacy Achievement in VERSATILE-002 Phase 2 Trial of PDS0101 in Combination With KEYTRUDA® (pembrolizumab) in Advanced Head and Neck Cancer
Published: 2022-02-02 (Crawled : 14:00) - biospace.com/
PDSB | $3.165 5.85% 180K

Health Technology

| -50.82% | O: -8.22% H: 0.0% C: 0.0%
atile-002 keytruda phase 2 trial cancer biotech iot

PDS Biotech Announces Preclinical Data for PDS0202 Universal Influenza Vaccine
Published: 2022-01-27 (Crawled : 14:00) - biospace.com/
PDSB | $3.165 5.85% 180K

Health Technology

| -42.5% | O: 1.15% H: 5.85% C: -9.13%
pds0202 preclinical biotech vaccine influenza iot pre-clinical

PDS Biotech Reports An Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Published: 2021-12-23 (Crawled : 21:00) - globenewswire.com
PDSB | $3.165 5.85% 180K

Health Technology

| Email alert Add to watchlist
nasdaq biotech iot granted grant

PDS Biotech Provides Recruitment update for National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based CombinationInstitutional Review Board (IRB) approval has been obtained and clinical trial recruitment resumes
Published: 2021-12-06 (Crawled : 15:30) - biospace.com/
PDSB | $3.165 5.85% 180K

Health Technology

| -64.49% | O: -2.14% H: 0.0% C: 0.0%
phase 2 trial approval cancer biotech iot

PDS Biotech Provides Business Update and Reports Third Quarter 2021 Financial Results
Published: 2021-11-10 (Crawled : 12:15) - globenewswire.com
PDSB | $3.165 5.85% 180K

Health Technology

| -73.61% | O: -7.24% H: 2.21% C: -2.95%
financial results results biotech iot

PDS Biotech Announces Agreement with University of Georgia to License Novel Proteins for Versamune-based Universal Flu Vaccine
Published: 2021-11-01 (Crawled : 13:00) - globenewswire.com
PDSB | $3.165 5.85% 180K

Health Technology

| -75.17% | O: 0.08% H: 6.13% C: 3.98%
biotech vaccine license iot

PDS Biotech Chief Medical Officer, Lauren V. Wood, to Present at the 2021 International Head and Neck Cancer Conference
Published: 2021-10-27 (Crawled : 13:00) - globenewswire.com
PDSB | $3.165 5.85% 180K

Health Technology

| -74.55% | O: -0.26% H: 2.26% C: -0.51%
cancer biotech iot conference

PDS Biotech Provides Update on National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based CombinationTemporary administrative suspension of recruitment
Published: 2021-10-21 (Crawled : 12:00) - biospace.com/
PDSB | $3.165 5.85% 180K

Health Technology

| -75.19% | O: -3.24% H: 3.52% C: -0.69%
phase 2 cancer biotech iot trial

PDS Biotechnology Announces Conference Call and Webcast to Present Third-Quarter 2021 Financial Results
Published: 2021-10-13 (Crawled : 21:00) - globenewswire.com
PDSB | $3.165 5.85% 180K

Health Technology

| -78.22% | O: 0.8% H: 2.13% C: -1.73%
financial results results biotech technology iot conference

PDS Biotechnology Welcomes Matthew Hill as Chief Financial Officer
Published: 2021-10-06 (Crawled : 13:15) - globenewswire.com
PRGO | $30.38 1.07% 42K

Health Technology

| -37.93% | O: -0.58% H: 1.25% C: 0.77%
SSKN | $0.53 110

Health Technology

| -72.11% | O: -0.53% H: 1.06% C: 0.53%
PDSB | $3.165 5.85% 180K

Health Technology

| -79.16% | O: -2.58% H: 2.5% C: -1.65%
biotech technology iot

PDS Biotech Enrolls First Stage of Checkpoint Inhibitor Naïve Patient Arm of Phase 2 Clinical Trial in Advanced HPV-16 Positive Head and Neck Cancer
Published: 2021-10-04 (Crawled : 13:00) - globenewswire.com
PDSB | $3.165 5.85% 180K

Health Technology

| -79.85% | O: -4.78% H: 2.41% C: 0.0%
phase 2 positive hpv cancer biotech iot trial enroll

PDS Biotechnology to Present at the Benzinga Healthcare Conference
Published: 2021-09-27 (Crawled : 13:15) - globenewswire.com
PDSB | $3.165 5.85% 180K

Health Technology